Skip to content

Pain Relieving Effect of Glycerol Trinitrate (GTN) in Renal Colic

Pain Relieving Effect of Glycerol Trinitrate (GTN) in Renal Colic: a Randomized Placebo-Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180428039443N2
Enrollment
100
Registered
2021-04-06
Start date
2021-02-12
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Colic. Unspecified renal colic

Interventions

Intervention 1: Intervention group: Patients who receive, in addition to standard treatment Glycerol Trinitrate (GTN). GTN sprays contain 0.4 mg of trinitroglycerin. Intervention 2: Control group: Pat

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 16 years of age, who are clinically diagnosed by an emergency physician with imaging (ultrasound or CT scan) to have renal colic and have a pain level higher than 5 on the VAS scale). Patients who have treated themselves or had side effects from diseases such as gastrointestinal, heart, kidney or liver are not included. The following will be considered as exclusion criteria: symptoms of peritoneal irritation, pregnancy and lactation, fever or hypotension; History of sildenafil, tadalafil, vardenafil, antihypertensive drugs, aspirin, antimuscarinic, alcohol, ergotamine, haloperidol or phenothiazine during the last 4 weeks,

Exclusion criteria

Exclusion criteria: allergic reaction to GTN; Severe clinical anemia; Recent concussion or any damage to the central nervous system, malnutrition, hypothyroidism; Hypothermia; And drug abusers.

Design outcomes

Primary

MeasureTime frame
Pain Relieving. Timepoint: Pain will be measured again in patients after 5 minutes, and if the VAS pain is still more than 5, the patient will receive another 30 mg of ketorolac injection. Pain will be re-estimated 30 minutes after this dose, and if the patient has a VAS pain score higher than 5, the next dose of ketorolac will be injected. Method of measurement: Response to VAS treatment is defined as less than 5.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Reza Dehpour

Tehran University of Medical Sciences

dehpour@yahoo.com+98 21 8897 3652

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026